Encompass Health Co. (NYSE:EHC) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group reduced its holdings in Encompass Health Co. (NYSE:EHC) by 19.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 576,716 shares of the company’s stock after selling 140,431 shares during the quarter. Schroder Investment Management Group owned 0.57% of Encompass Health worth $53,300,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after buying an additional 137 shares in the last quarter. CBIZ Investment Advisory Services LLC raised its position in shares of Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after purchasing an additional 127 shares during the period. Tompkins Financial Corp purchased a new stake in shares of Encompass Health during the fourth quarter valued at $46,000. V Square Quantitative Management LLC boosted its position in shares of Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock valued at $54,000 after purchasing an additional 177 shares during the period. Finally, Morse Asset Management Inc purchased a new position in Encompass Health in the 3rd quarter worth about $68,000. 97.25% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 2.10% of the company’s stock.

Encompass Health Stock Up 0.6 %

EHC opened at $101.40 on Tuesday. The company has a market capitalization of $10.21 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 2.31 and a beta of 0.92. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. Encompass Health Co. has a fifty-two week low of $78.53 and a fifty-two week high of $104.55. The business has a 50-day moving average of $98.81 and a 200-day moving average of $97.52.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Equities research analysts forecast that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Tuesday, April 1st. Encompass Health’s dividend payout ratio is presently 15.25%.

Analysts Set New Price Targets

Several brokerages have commented on EHC. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, February 15th. KeyCorp lifted their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Royal Bank of Canada reissued an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a research note on Tuesday, February 11th. Barclays raised their target price on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Finally, William Blair reissued an “outperform” rating on shares of Encompass Health in a research note on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.